Janet Brutschea Haugen - 30 Sep 2026 Form 4 Insider Report for WEST PHARMACEUTICAL SERVICES INC (WST)

Reporting relationship: Director
Issuer ticker: WST
Reported as of: 30 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Oct 2026, 13:10:42 UTC
Prior SEC filing: 01 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Louis Lalli, as an agent for Janet Brutschea Haugen

Key filing fact

Janet Brutschea Haugen filed Form 4 for WEST PHARMACEUTICAL SERVICES INC (WST) on 02 Oct 2026.

Key facts

This page summarizes Janet Brutschea Haugen's Form 4 filing for WEST PHARMACEUTICAL SERVICES INC (WST).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Oct 2026, 13:10.

Change

Previous filing in this sequence was filed on 01 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001185136 Primary reporting owner

HAUGEN JANET BRUTSCHEA

Relationship: Director
Address: 530 HERMAN O. WEST DRIVE, EXTON
Signature: /s/ Louis Lalli, as an agent for Janet Brutschea Haugen
Signature date: 02 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WST holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,114
Date: 30 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WST transaction Derivative

Phantom Stock Unit

Award

Transaction value
Shares: +44
Change %: +14%
Price: $370.76^*
Shares after: 351
Date: 30 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 44
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects 791 shares of restricted stock units and dividend equivalents that will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

Footnote F2

Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director.